Insempra, an IZB-based biology-powered company enabling businesses to make superior products in collaboration with nature, announced the successful completion of a $20 million Series A financing round in early May 2024.

Following an initial $15m seed round conducted in 2021, this financing round will enable Insempra, to continue building a technology platform that delivers high-performance, intrinsically sustainable ingredients for a wide range of industries, while supporting the company in the scale up of its technology scouting, development, and manufacturing capabilities.

Existing investors EQT Ventures, BlueYard Capital, Possible Ventures, Taavet Sten and Acequia Capital participated in the round. New investors are the corporate venture of international FMCG giant Henkel, Henkel dx Ventures, Bayern Kapital and Alante Capital.

Inspired to create a better future in collaboration with nature, Insempra takes a market-first approach to developing its science, creating ingredients that customers need. By harnessing new technologies to advance biological manufacturing processes, the company creates naturally superior products to drive the regenerative revolution. Insempra designs and builds these ingredients with atomic precision so that they can be rapidly produced and manufactured at scale, offering better solutions to agriculturally and petrochemically sourced oils and materials.

Driven by market need and collaborations with world-wide renowned consumer brands, Insempra is growing lipids for cosmetic and food applications. It is also developing technology that offers a bio-based alternative to everyday materials such as polymers and textiles and progressing its biological solutions to create new natural molecules for use in functional ingredients, such as antioxidants and preservatives and flavours and fragrances.

The Company’s founder, Jens Klein has a proven track record in developing biology-powered technologies. Jens Klein is a serial entrepreneur and an expert in the development and scale-up of biologically superior ingredients, having formerly served as CEO of AMSilk GmbH, the world-leading first industrial supplier of vegan silk polymers.

Jens Klein, founder, and CEO of Insempra, commented: “We are grateful for the support of this group of investors who have recognized the potential of Insempra’s market-first approach and innovative technology platforms. Working in collaboration with nature, we will continue to expand our capacity to develop intrinsically sustainable materials that are superior in quality and will reduce our dependency on chemical industrialization processes.”

Ted Persson, Partner at EQT Ventures, added: “Insempra has both the team and the technology to drive a revolution in industrial manufacturing and gain rapid market traction for its products. New technology platforms such as Insempra’s have the potential to dramatically change the manufacturing processes of multiple multibillion-dollar industries, developing customized ingredients to fit market needs.”

About Insempra
Insempra is a biotechnology-powered company enabling businesses to transform their ingredient lists with superior products made in collaboration with nature.

For too long, businesses have relied on petrochemical production and environmental exploitation, depleting our limited natural resources, and polluting our planet.

Environmental issues, consumer demand, and regulatory restrictions are changing the ingredients landscape dramatically. The beauty & personal care, food & nutrition and fashion industries are under immense pressure to shift to sustainable alternatives.

Insempra’s advanced technology platform enables the production of superior natural ingredients at industrial scale to help the world’s leading brands to transform their products.

Together it is our mission to grow a better future.

Learn more about Insempra at: insempra.bio